Evidence map›Paper›PMID 30395621›Full record

ArticlePloS one2018

Mutant myocilin impacts sarcomere ultrastructure in mouse gastrocnemius muscle.

Jeffrey M Lynch, Andrew J Dolman, Chenying Guo, Katie Dolan, Chuanxi Xiang, Samir Reda, Bing Li, Ganesh Prasanna

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Inducible rodent models of glaucoma.Progress in retinal and eye research · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jeffrey M LynchOphthalmology, Novartis Institutes for BioMedical Research, Cambridge, MA, United States of America.ORCID 0000-0002-4042-7872
Andrew J DolmanOphthalmology, Novartis Institutes for BioMedical Research, Cambridge, MA, United States of America.
Chenying GuoOphthalmology, Novartis Institutes for BioMedical Research, Cambridge, MA, United States of America.
Katie DolanOphthalmology, Novartis Institutes for BioMedical Research, Cambridge, MA, United States of America.
Chuanxi XiangOphthalmology, Novartis Institutes for BioMedical Research, Cambridge, MA, United States of America.
Samir RedaOphthalmology, Novartis Institutes for BioMedical Research, Cambridge, MA, United States of America.
Bing LiOphthalmology, Novartis Institutes for BioMedical Research, Cambridge, MA, United States of America.
Ganesh PrasannaOphthalmology, Novartis Institutes for BioMedical Research, Cambridge, MA, United States of America.
Novartis (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocilin (MYOC) is the gene with mutations most common in glaucoma. In the eye, MYOC is in trabecular meshwork, ciliary body, and retina. Other tissues with high MYOC transcript levels are skeletal muscle and heart. To date, the function of wild-type MYOC remains unknown and how mutant MYOC causes high intraocular pressure and glaucoma is ambiguous. By investigating mutant MYOC in a non-ocular tissue we hoped to obtain novel insight into mutant MYOC pathology. For this study, we utilized a transgenic mouse expressing human mutant MYOC Y437H protein and we examined its skeletal (gastrocnemius) muscle phenotype. Electron micrographs showed that sarcomeres in the skeletal muscle of mutant CMV-MYOC-Y437H mice had multiple M-bands. Western blots of soluble muscle lysates from transgenics indicated a decrease in two M-band proteins, myomesin 1 (MYOM1) and muscle creatine kinase (CKM). Immunoprecipitation identified CKM as a MYOC binding partner. Our results suggest that binding of mutant MYOC to CKM is changing sarcomere ultrastructure and this may adversely impact muscle function. We speculate that a person carrying the mutant MYOC mutation will likely have a glaucoma phenotype and may also have undiagnosed muscle ailments or vice versa, both of which will have to be monitored and treated.

Indexed as

MutationAnimalsCytoskeletal ProteinsDisease Models, AnimalEye ProteinsFemaleGene ExpressionGlaucoma, Open-AngleGlycoproteinsHumansIntraocular PressureMaleMiceMice, Mutant StrainsMice, TransgenicMicroscopy, Electron, TransmissionCytoskeletal ProteinsEye ProteinsGlycoproteinsMutant ProteinsMyocilinRecombinant Proteins

Identifiers

PMID30395621
PMCPMC6218065
OpenAlexW2900042245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.